<DOC>
	<DOCNO>NCT02559544</DOCNO>
	<brief_summary>Evaluate [ 18F ] FES PET/CT uptake predictor progression free survival endocrine refractory recurrent metastatic breast cancer patient start new therapy regimen include endocrine target therapy .</brief_summary>
	<brief_title>18FFluoroestradiol ( FES ) PET/CT Imaging Evaluate Vivo Estrogen Receptor Activity Endocrine Refractory Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>1 . At least 18 year age 2 . Recurrent metastatic cancer know suspect breast origin may biopsy proven identify standard imaging ( e.g . CT , bone scan , MRI , FDG PET/CT ) 3 . History ER+ pathology ( ER+ may confirm surgery biopsy primary breast cancer lymph node , and/or surgery biopsy metastatic site , metastatic biopsy require ) 4 . At least one site disease outside liver see standard imaging ( e.g . CT , bone scan , MRI , FDG PET/CT ) ; patient measurable nonmeasurable disease allow . 5 . History progression recurrence disease endocrine target therapy contain regimen assess medical record review breast cancer history screen 6 . Participants must inform investigational nature study provide write informed consent accordance institutional federal guideline prior studyspecific procedure . 1 . Females pregnant time screen eligible study , urine pregnancy test perform screen woman childbearing potential . 2 . Inability tolerate image procedure opinion investigator treat physician 3 . Serious unstable medical psychological condition , opinion investigator , would compromise subject 's safety successful participation study . 4 . History HER2/neu positive cancer ( IHC 3+ and/or FISH positive ) assess medical record review screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>fail prior endocrine therapy</keyword>
</DOC>